- Home
- SPRO vs OBIO Comparison
SPRO vs OBIO Comparison
Compare SPRO & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- OBIO
- Stock Information
- Founded
- SPRO 2013
- OBIO 2017
- Country
- SPRO United States
- OBIO United States
- Employees
- SPRO N/A
- OBIO N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- SPRO Health Care
- OBIO Health Care
- Exchange
- SPRO Nasdaq
- OBIO Nasdaq
- Market Cap
- SPRO 107.5M
- OBIO 118.8M
- IPO Year
- SPRO 2017
- OBIO N/A
- Fundamental
- Price
- SPRO $1.87
- OBIO $2.55
- Analyst Decision
- SPRO Buy
- OBIO Strong Buy
- Analyst Count
- SPRO 4
- OBIO 4
- Target Price
- SPRO $5.00
- OBIO $14.67
- AVG Volume (30 Days)
- SPRO 798.2K
- OBIO 451.7K
- Earning Date
- SPRO 08-12-2025
- OBIO 08-12-2025
- Dividend Yield
- SPRO N/A
- OBIO N/A
- EPS Growth
- SPRO N/A
- OBIO N/A
- EPS
- SPRO N/A
- OBIO N/A
- Revenue
- SPRO $48,576,000.00
- OBIO $2,944,000.00
- Revenue This Year
- SPRO N/A
- OBIO $19.83
- Revenue Next Year
- SPRO N/A
- OBIO $12.53
- P/E Ratio
- SPRO N/A
- OBIO N/A
- Revenue Growth
- SPRO N/A
- OBIO 41.61
- 52 Week Low
- SPRO $0.51
- OBIO $2.37
- 52 Week High
- SPRO $3.22
- OBIO $7.04
- Technical
- Relative Strength Index (RSI)
- SPRO 35.23
- OBIO 42.61
- Support Level
- SPRO $1.80
- OBIO $2.50
- Resistance Level
- SPRO $2.38
- OBIO $2.75
- Average True Range (ATR)
- SPRO 0.12
- OBIO 0.14
- MACD
- SPRO -0.02
- OBIO -0.01
- Stochastic Oscillator
- SPRO 12.07
- OBIO 42.50
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.